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Metabolic imbalances accompany the aging process in many organisms, and signaling mecha-
nisms that allay or prevent these imbalances can extend lifespan. Two recent studies by Auwerx
and colleagues, including one in this issue, identify a conserved signaling network centered on
mitochondrial stress responses that promotes longevity in response to changes in mitochondrial
translation and NAD+ metabolism.Aging is characterized by a progressive
decline in metabolic homeostasis. A
comprehensive insight into cellular pro-
cesses that respond to metabolic imbal-
ances will be useful in identifying new
avenues for therapeutic intervention
against age-related diseases.
Mitochondria play a central role in such
processes, as they are the hubs of meta-
bolic activity in eukaryotic cells and signif-
icantly influence the intracellular energy
balance and redox milieu. The function
of mitochondria as sensors of metabolic
imbalances and as mediators of specific
cellular stress responses that can impact
longevity has recently garnered increased
attention. Mitochondrial dysfunction has
long been implicated in aging, primarily
as a source of metabolic stress and of
reactive oxygen species (ROS; Balaban
et al., 2005). However, recent work in
C. elegans has shown that specific stress
responses initiated by mitochondria that
experience functional impairments can
extend lifespan. These stress responses
include both the mitochondrial unfolded
protein response (UPRmt; Durieux
et al., 2011) and mitochondrial ROS-
induced defense pathways (mitohormesisresponse; Lee et al., 2010; Schulz et al.,
2007).
In a recent genetic tour-de-force,
Auwerx and colleagues have identified
mutations in mitochondrial ribosomal pro-
teins (MRPs) as evolutionarily conserved
regulators of lifespan (Houtkooper et al.,
2013). Genetic variants of MRPS5 expres-
sion in mice significantly correlate with
increased longevity, whereas MRP
knockdown in C. elegans can extend life-
span. These phenotypes are associated
with ‘‘mitonuclear imbalance,’’ an imbal-
ance between the expression of nuclear-
and mitochondrially encoded mitochon-
drial proteins. Mitonuclear imbalance
activates the UPRmt, extending lifespan
in C. elegans. Interestingly, longevity-
promoting compounds such as rapamy-
cin and resveratrol also induce mitonu-
clear imbalance, and the UPRmt is
required for rapamycin-mediated lifespan
extension in worms (Houtkooper et al.,
2013). The authors further identify specific
antibiotics that induce mitonuclear imbal-
ance, activate the UPRmt, and extend life-
span.
Now, in this issue of Cell, the Auwerx
group extends this work and identifieshow a central metabolic intermediate,
nicotinamide adenine dinucleotide
(NAD+), influences mitochondrial stress
responses (Mouchiroud et al., 2013).
NAD+ governs cellular energy homeosta-
sis through its central role inmitochondrial
ATP production, and the maintenance of
an optimal NAD+/NADH ratio is critical
for mitochondrial function. Beyond ATP
production, the biosynthesis and catabo-
lism of NAD+, which can be modulated by
nutritional and environmental stimuli, also
influences the function of NAD+ -depen-
dent enzymes, such as sirtuins and poly-
ADP-ribose polymerase (PARP). Sirtuins,
which regulate many cellular metabolic
processes, influence lifespan in various
organisms, and significantly affect age-
related metabolic diseases in mice (Chal-
kiadaki and Guarente, 2012). PARPs, in
turn, are NAD+ consuming enzymes clas-
sically described as DNA repair proteins
(Ame´ et al., 2004).
NAD+ metabolism thus engages key
effectors of longevity, and interventions
aimed at modulating NAD+ levels may
have significant effects on longevity and
age-related diseases. Supporting this
notion, elevated NAD+ levels have been154, July 18, 2013 ª2013 Elsevier Inc. 271
Figure 1. A Trigger to Induce the Mitochondrial Unfolded Protein Response
In two new studies, ‘‘mitonuclear imbalance’’’ (an imbalance between the expression of nuclear and
mitochondrially encoded mitochondrial proteins) has been established as a trigger to induce the mito-
chondrial unfolded protein response (UPRMT) stress-signaling pathway, which can promote longevity in
C. elegans (Mouchiroud et al., 2013; Houtkooper et al., 2013). Inhibiting nuclear-encoded mitochondrial
ribosomal proteins (MRPs) can induce this imbalance and extend lifespan. Known longevity-promoting
compounds (rapamycin and resveratrol), antibiotics that target translation (doxycyclin), as well as
modulating NAD+ metabolism and the NAD+-dependent Sir2 (SirT1 in mammals; SIR-2.1 in C. elegans),
can also promote mitonuclear imbalance and the UPRMT. Mouchiroud et al. further uncover that a NAD+/
Sir2/UPRMT/Foxo-signaling axis can extend lifespan in C. elegans (right). Boosting NAD+ levels by
inhibiting poly-ADP-ribose polymerase (PARP/PME-1), or by nicotinamide precursor supplementation
(NAM/NR), can induce Sir2 activation and mitonuclear imbalance. Mitonuclear imbalance further initiates
both an early UPRMT and delayed ROS-mediated Foxo/DAF-16 activation that can promote lifespan
extension in C. elegans.associated with protective effects against
neurodegeneration and high-fat-diet-
induced obesity (Barbosa et al., 2007;
Belenky et al., 2007).Mouchiroud and col-
leagues confirm this model in C. elegans
and identify a role for the UPRmt and the
mitohormesis response in extending life-
span when NAD+ levels are increased.
The authors show that NAD+ levels natu-
rally decrease in aging worms and mice
due to an increase in PARP activity. Treat-
ing worms with inhibitors of PARP, or
mutating the worm PARP homolog
pme-1, increases NAD+ levels and
extends lifespan. PARP inhibitors are
considered potential therapeutic agents
for cancer, and inflammatory and neuro-
degenerative pathologies, suggesting
that the observed phenotypes may pro-
vide insight into treatment strategies for
such diseases (Ame´ et al., 2004).
The lifespan extension caused by PARP
inhibition in worms is dependent on the
C. elegans homolog of Sir2 (sir-2.1) and
can be mimicked by supplying the NAD+272 Cell 154, July 18, 2013 ª2013 Elsevier Inprecursors NAM or NR. Interestingly, acti-
vation of the UPRmt is also involved in this
response, as lifespan extension by PARP
inhibition and NAD supplementation
requires ubl-5, a required component of
the UPRmt. These results highlight a
causal link between NAD+ levels and
aging, as well as the integration of meta-
bolic networks, nutritional inputs, and
mitochondrial signaling in the control of
longevity.
To gain deeper mechanistic insight into
this response, the authors carry out tem-
poral analyses: At day 1 of adulthood,
PARP inhibition and NR supplementation
increases respiration, causes mitonu-
clear imbalance, suppresses mitochon-
drial fusion, activates the UPRmt, and
induces mitochondrial superoxide pro-
duction but does not induce nuclear
translocation or target gene expression
of the ROS-responsive transcription fac-
tor and longevity protein DAF-16/Foxo.
At day 3 of adulthood, however, PARP in-
hibition and NR supplementation also in-c.duces the UPRmt but increases mito-
chondrial fusion, nuclear localization of
DAF-16/Foxo, and expression of the anti-
oxidant target gene of DAF-16/Foxo,
sod-3. It is likely that this delayed activa-
tion of DAF-16/Foxo is part of an adap-
tive ‘‘mitohormesis’’ response to the
earlier spike in mitochondrial ROS
production.
Finally, the authors show that NAD+
supplementation and SirT1 activation
induces stress responses in mammalian
hepatocytes that are reminiscent of the
UPRmt and the DAF-16-mediated stress
response in worms.
Taken together, Mouchiroud et al. pre-
sent an evolutionarily conserved NAD+/
Sir2/UPRmt/Foxo-signaling axis that can
extend lifespan in C. elegans. It is of
particular interest that NAD+ metabolism
can coordinate the activity of known me-
diators of longevity, such as Sir2 and
Foxo, supporting a model in which NAD+
levels are a key determinant of aging via
the integration of metabolic, dietary, and
mitochondrial inputs (Figure 1). The
conserved nature of these interactions
should invite future work to explore
whether pharmacologically targeting
NAD+ metabolism (potentially using
PARP inhibitors) can prevent age-associ-
ated diseases.
Importantly, this and previous studies
also highlight the central role of the UPRmt
in monitoring fluctuations in cellular
metabolism and promoting protective
responses that increase lifespan. Future
studies dissecting the signaling mecha-
nisms involved in these responses thus
have the potential to significantly advance
our understanding of aging and age-
related diseases.ACKNOWLEDGMENTS
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